Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10442189 | 1.00 | ECE1 (0.40) | ECE1LMNAALOX15BLMPMP22 | |
| SCHEMBL13233706 | 1.00 | ECE1 (0.40) | ECE1LMNAALOX15BLMPMP22 | |
| SCHEMBL992852 | 0.88 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL992850 | 0.88 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL24915343 | 0.88 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL20342164 | 0.82 | — | — | |
| SCHEMBL14417629 | 0.81 | ECE1 (0.42) | ECE1 | |
| SCHEMBL515169 | 0.81 | ECE1 (0.49) | ECE1ALOX15BLMITGB2ICAM1 | |
| SCHEMBL15866495 | 0.81 | ECE1 (0.37) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL160994 | 0.81 | ECE1 (0.49) | ECE1ALOX15BLMITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-3925667-A1 | SELECTIVE TMPRSS2 INHIBITORS AND MEDICAL USE THEREOF | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021186166-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019202052-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201432-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | WO | disclosed |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| WO-2010042525-A9 | OVARIAN CANCER BIOMARKERS AND USES THEREOF | SOMALOGIC, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-1857466-B1 | Soluble interleukin-20 receptor | ZYMOGENETICS INC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010042525-A1 | OVARIAN CANCER BIOMARKERS AND USES THEREOF | SOMALOGIC, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20090274091-A1 | SYSTEM FOR INTERCONNECTING BROADBAND WIRELESS NETWORK WITH WIRED NETWORK | HUAWEI TECHNOLOGIES CO., LTD. (CN) | 2009-11-05 | — | — | US | disclosed |
| WO-2009126292-A2 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1585752-B1 | POLYENE POLYKETIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL | THALLION PHARMACEUTICALS INC (CA) | 2007-11-21 | — | — | EP | disclosed |
| US-20070184513-A1 | Substrates for beta-lactamase and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-08-09 | — | — | US | disclosed |
| EP-1816213-A2 | Novel DNA polymerase III holoenzyme delta subunit nucleic acid molecules and proteins | Replidyne, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7179472-B2 | Involving nucleotide sequence 15 or 19; efficient, well tolerated | WYETH (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070031864-A1 | Polyvalent cation-sensing receptor in atlantic salmon | HARRIS H W JR | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147478-A1 | INHIBITORS OF BLOOD COAGULATION FACTOR XIII | TFPI, F11, F13B | ECE1 120/4885LMNA 1300/4885ALOX15 1825/4885 |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | GLP1R, GIPR, NPY4R | ECE1 1762/4885LMNA 2577/4885ALOX15 1555/4885 |
| US-20190322700-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | ECE1 409/4885LMNA 2426/4885ALOX15 1310/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | ECE1 409/4885LMNA 2426/4885ALOX15 1310/4885 |
| US-20070184513-A1 | Substrates for beta-lactamase and uses thereof | CMBL, DBH, NCEH1 | ECE1 2355/4885LMNA 1658/4885ALOX15 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.